131 related articles for article (PubMed ID: 23394928)
21. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication.
Mahoney KM; Ackerman A; Cho DC; McDermott DF; Peters T; Atkins MB
J Clin Oncol; 2013 Jul; 31(21):e364-6. PubMed ID: 23752114
[No Abstract] [Full Text] [Related]
23. Delayed oral toxicity from long-term vemurafenib therapy.
Lloyd-Lavery A; Hodgson T; Coupe N; Bond S; Shah K; Espinosa O; Payne MJ; Middleton MR; Matin RN
Br J Dermatol; 2016 May; 174(5):1159-60. PubMed ID: 26853702
[No Abstract] [Full Text] [Related]
24. Another adverse effect of vemurafenib: Gingival hyperplasia.
Salman A; Tekin B; Koca S; Akgul Babacan N; Yumuk PF; Ergun T
J Dermatol; 2016 Jun; 43(6):706-7. PubMed ID: 26703083
[No Abstract] [Full Text] [Related]
25. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.
Harding JJ; Barker CA; Carvajal RD; Wolchok JD; Chapman PB; Lacouture ME
J Clin Oncol; 2014 May; 32(14):e54-6. PubMed ID: 24470011
[No Abstract] [Full Text] [Related]
26. Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
Trappe R; Budde U; Zimmermann H
Thromb Haemost; 2012 Oct; 108(4):798-800. PubMed ID: 22918265
[No Abstract] [Full Text] [Related]
27. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
28. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
29. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?
Reigneau M; Granel-Brocard F; Geoffrois L; Bauman AS; Tréchot P; Barbaud A; Schmutz JL
Eur J Dermatol; 2013; 23(4):544-5. PubMed ID: 24001519
[No Abstract] [Full Text] [Related]
30. Sarcoidosis associated with vemurafenib.
Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
[No Abstract] [Full Text] [Related]
31. Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?
Gey A; Milpied B; Dutriaux C; Mateus C; Robert C; Perro G; Taieb A; Ezzedine K; Jouary T
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):178-9. PubMed ID: 25175726
[No Abstract] [Full Text] [Related]
32. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
33. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
34. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
35. Facial acneiform rash associated with sorafenib.
Fleta-Asín B; Vañó-Galván S; Ledo-Rodríguez A; Truchuelo-Díez M; Jaén-Olasolo P
Dermatol Online J; 2009 Apr; 15(4):7. PubMed ID: 19450400
[TBL] [Abstract][Full Text] [Related]
36. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R; Lecamwasam K; Purshouse K; Reed J; Middleton MR; Fearfield L
Br J Dermatol; 2014 Apr; 170(4):997-9. PubMed ID: 24359127
[No Abstract] [Full Text] [Related]
37. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
38. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
39. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment.
Kouros P; Gerding H
Klin Monbl Augenheilkd; 2016 Apr; 233(4):488-9. PubMed ID: 27116515
[No Abstract] [Full Text] [Related]
40. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
Longhurst WD; Honda K; Koon HB; Gerstenblith MR
Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
